Brainomix e-Lung is an FDA-cleared, AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans enabling clinicians to more easily identify changes including subtle deteriorations over multiple scan timepoints.

Patients with ILD can develop Progressive Pulmonary Fibrosis (PPF), which causes irreversible lung damage and leads to early mortality. The key to the best outcome and survival for patients is early initiation of treatment. However, identifying patients eligible for treatment based on imaging can be challenging, even for experts.

AI-powered CT analysis has the potential to transform pulmonary fibrosis care. With it, doctors can enhance early detection, precisely quantify disease, and track progression over time.

"The data we have shown for e-Lung is very promising, and the ability to objectively assess parenchymal changes to predict disease trajectory and treatment responses could really help us personalize treatment decisions and improve outcomes for patients living with pulmonary fibrosis," said Dr Teja Kulkarni, Associate Professor and Director of the ILD Program at the University of Alabama at Birmingham.

Through a research collaboration and partnership with Boehringer Ingelheim, the global leader in pulmonary fibrosis therapies, Brainomix were granted privileged access to the landmark INBUILD clinical trial dataset to run the first quantitative CT analysis.

The analysis used quantitative CT measurements. These measurements were used by the authors to accurately and sensitively facilitate identification of PPF, and establish the value of quantitative metrics as a prognostic tool for the assessment of PPF progression.

“The technology [e-Lung] may help in monitoring disease progression and tailoring treatment plans to patients individually. This will ultimately improve outcomes and quality of life for those affected,” Martin Beck, Therapeutic Area Head for Inflammation, Boehringer Ingelheim.

Click here to read more of Martin's interview.